#Novartis' oral #BTKinhibitor #Rhapsido has had its label expanded in the #US to include a second indication, #symptomaticdermographism (SD), which causes #chronichives.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social
@gmj-georgia.bsky.socialTriple therapy breakthrough: Adding pirtobrutinib to venetoclax-rituximab significantly extends progression-free survival in patien… #BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax #BTKinhibitor #Chroniclymphocyticleukemia #Pirtobrutinib #Rituximab #Venetoclax h…